The Uncertainty Surrounding the Burden of Post-acute Consequences of Dengue Infection

Hung, Trinh Manh; Wills, Bridget; Clapham, Hannah E.; Yacoub, Sophie; Turner, Hugo C.

doi:10.1016/j.pt.2019.06.004

Cited by 20 publications

(20 citation statements)

References 15 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we acknowledge that estimates of the transition to, and duration of, post-acute consequences remain largely uncertain. [26][27][28][29] In our sensitivity analyses, we have shown that a wide range of assumptions have a minimal impact on DALY estimates, given that YLD only contributes around 2% to total DALYs. As further epidemiological information on post-acute consequences emerge, they can be integrated into our estimation process to increase the certainty of our point estimates of YLD.…”

Section: Strengths and Weaknessesmentioning

confidence: 99%

Measuring the direct population impact of COVID-19 in Scotland, 2020: estimating disability-adjusted life years (DALYs) during the first full calendar year

Wyper¹,

Fletcher²,

Grant³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Disability-adjusted life years (DALYs) combine the impact of morbidity and mortality and can enable comprehensive, and comparable, assessments of direct and indirect health harms due to COVID-19. Our aim was to estimate DALYs directly due to COVID-19 in Scotland, during 2020; and contextualise its population impact relative to other causes of disease and injury.Methods: National deaths and daily case data were used. Deaths were based on underlying and contributory causes recorded on death certificates. We calculated DALYs based on the COVID-19 consensus model and methods outlined by the European Burden of Disease Network. DALYs were presented as a range, using a sensitivity based on Years of Life Lost estimates using: cause-specific; and COVID-19 related deaths. All estimates were for 2020.Findings: In 2020, estimates of COVID-19 DALYs in Scotland ranged from 96,500 to 108,200. Direct COVID-19 DALYs were substantial enough to be framed as the second leading cause of disease and injury, with only ischaemic heart disease having a larger impact on population health. Mortality contributed 98% of total DALYs.Interpretation: The direct population health impact of COVID-19 has been very substantial. Despite unprecedented mitigation efforts, COVID-19 developed from a single identified case in early 2020 to a condition with an impact in Scotland second only to ischaemic heart disease. Periodic estimation of DALYs during 2021, and beyond, will provide indications of the impact of DALYs averted due to the national roll-out of the vaccination programme and other continued mitigation efforts, although new variants may pose significant challenges.

show abstract

Section: Strengths and Weaknessesmentioning

confidence: 99%

Measuring the direct population impact of COVID-19 in Scotland, 2020: estimating disability-adjusted life years (DALYs) during the first full calendar year

Wyper¹,

Fletcher²,

Grant³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The majority of the studies we identified within this review would not have a long enough follow-up period to fully capture the potential impact of these post-acute consequences on the estimated productivity losses of dengue. The incidence, duration and severity of these post-acute consequences is a key area of uncertainty regarding the burden of dengue [49]. Currently, the majority of studies in this area are from Latin America, and more research is needed from other settings (particularly higher transmission settings, where the age of distribution of episodes differs) [49].…”

Section: Resultsmentioning

confidence: 99%

“…The incidence, duration and severity of these post-acute consequences is a key area of uncertainty regarding the burden of dengue [49]. Currently, the majority of studies in this area are from Latin America, and more research is needed from other settings (particularly higher transmission settings, where the age of distribution of episodes differs) [49].…”

Section: Resultsmentioning

confidence: 99%

Productivity costs from a dengue episode in Asia: a systematic literature review

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Dengue is a mosquito-borne viral infection which has been estimated to cause a global economic burden of US$8.9 billion per year. 40% of this estimate was due to what are known as productivity costs (the costs associated with productivity loss from both paid and unpaid work that results from illness, treatment or premature death). Although productivity costs account for a significant proportion of the estimated economic burden of dengue, the methods used to calculate them are often very variable within health economic studies. The aim of this review was to systematically examine the current estimates of the productivity costs associated with dengue episodes in Asia and to increase awareness surrounding how productivity costs are estimated. Method We searched PubMed and Web of Knowledge without date and language restrictions using terms related to dengue and cost and economics burden. The titles and abstracts of publications related to Asia were screened to identify relevant studies. The reported productivity losses and costs of non-fatal and fatal dengue episodes were then described and compared. Costs were adjusted for inflation to 2017 prices. Results We reviewed 33 relevant articles, of which 20 studies reported the productivity losses, and 31 studies reported productivity costs. The productivity costs varied between US$6.7–1445.9 and US$3.8–1332 for hospitalized and outpatient non-fatal episodes, respectively. The productivity cost associated with fatal dengue episodes varied between US$12,035-1,453,237. A large degree of this variation was due to the range of different countries being investigated and their corresponding economic status. However, estimates for a given country still showed notable variation. Conclusion We found that the estimated productivity costs associated with dengue episodes in Asia are notable. However, owing to the significant variation in methodology and approaches applied, the reported productivity costs of dengue episodes were often not directly comparable across studies. More consistent and transparent methodology regarding the estimation of productivity costs would help the estimates of the economic burden of dengue be more accurate and comparable across studies.

show abstract

“…Many patients who survive acute-Covid-19 experience persistent symptoms beyond 4 weeks, known as 'long-Covid' 8 . This includes a wide range of symptoms, such as breathlessness, fatigue, muscle pain, many of which overlap with PICS and other post-viral syndromes 1,[9][10][11][12][13][14][15][16] . The most common symptom of long-Covid described following both community and hospital-managed acute-Covid-19 was fatigue: fatigue was reported in 97.7% of community-managed cases who reported symptoms lasting over 28 days, and in 83% and 98% of UK and China patients respectively greater than 3-months after hospital discharge following admission with acute-Covid-19 11,16,17 .…”

Section: Introductionmentioning

confidence: 99%

Recovery from Covid-19 critical illness: a secondary analysis of the ISARIC4C CCP-UK cohort study and the RECOVER trial

Pauley

Drake

Griffith

et al. 2021

Preprint

View full text Add to dashboard Cite

Background We aimed to compare the prevalence and severity of fatigue in survivors of Covid-19 versus non-Covid-19 critical illness, and to explore potential associations between baseline characteristics and worse recovery. Methods We conducted a secondary analysis of two prospectively collected datasets. The population included was 92 patients who received invasive mechanical ventilation (IMV) with Covid-19, and 240 patients who received IMV with non-Covid-19 illness before the pandemic. Follow-up data was collected post-hospital discharge using self-reported questionnaires. The main outcome measures were self-reported fatigue severity and the prevalence of severe fatigue (severity >7/10) 3 and 12-months post-hospital discharge. Results Covid-19 IMV-patients were significantly younger with less prior comorbidity, and more males, than pre-pandemic IMV-patients. At 3-months, the prevalence (38.9% [7/18] vs. 27.1% [51/188]) and severity (median 5.5/10 vs. 5.0/10) of fatigue was similar between the Covid-19 and pre-pandemic populations respectively. At 6-months, the prevalence (10.3% [3/29] vs. 32.5% [54/166]) and severity (median 2.0/10 vs. 5.7/10) of fatigue was less in the Covid-19 cohort. In the Covid-19 population, women under 50 experienced more severe fatigue, breathlessness, and worse overall health state compared to other Covid-19 IMV-patients. There were no significant sex differences in long-term outcomes in the pre-pandemic population. In the total sample of IMV-patients included (i.e. all Covid-19 and pre-pandemic patients), having Covid-19 was significantly associated with less severe fatigue (severity <7/10) after adjusting for age, sex, and prior comorbidity (adjusted OR 0.35 (95%CI 0.15-0.76, p=0.01). Conclusion. Fatigue may be less severe after Covid-19 than after other critical illness.

show abstract

The Uncertainty Surrounding the Burden of Post-acute Consequences of Dengue Infection

Cited by 20 publications

References 15 publications

Measuring the direct population impact of COVID-19 in Scotland, 2020: estimating disability-adjusted life years (DALYs) during the first full calendar year

Measuring the direct population impact of COVID-19 in Scotland, 2020: estimating disability-adjusted life years (DALYs) during the first full calendar year

Productivity costs from a dengue episode in Asia: a systematic literature review

Recovery from Covid-19 critical illness: a secondary analysis of the ISARIC4C CCP-UK cohort study and the RECOVER trial

Contact Info

Product

Resources

About